{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:51:44Z","timestamp":1792547504232,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004933","name":"Instituto Nacional de Ci\u00eancia e Tecnologia em Toxinas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004933","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Minas Gerais State Foundation of Support to the Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.lana.2025.101059","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T05:44:23Z","timestamp":1742622263000},"page":"101059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The time has come for a vaccine against Chagas disease"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2588-2842","authenticated-orcid":false,"given":"Santuza M.","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela de A.","family":"Burle-Caldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia T.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo T.","family":"Gazzinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9723","key":"10.1016\/j.lana.2025.101059_bib1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","article-title":"Chagas disease","volume":"375","author":"Rassi","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lana.2025.101059_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.100972","article-title":"Challenges and advancements in the development of vaccines and therapies against Chagas disease","volume":"5","author":"Pinazo","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lana.2025.101059_bib3","doi-asserted-by":"crossref","first-page":"e210193","DOI":"10.1590\/0074-02760210193","article-title":"Trypanosoma cruzi genetic diversity: impact on transmission cycles and Chagas disease","volume":"117","author":"Zingales","year":"2022","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"6","key":"10.1016\/j.lana.2025.101059_bib4","doi-asserted-by":"crossref","first-page":"e0231922","DOI":"10.1128\/mbio.02319-22","article-title":"Accessing the variability of multicopy genes in complex genomes using unassembled next-generation sequencing reads: the case of Trypanosoma cruzi multigene families","volume":"13","author":"Reis-Cunha","year":"2022","journal-title":"mBio"},{"issue":"2","key":"10.1016\/j.lana.2025.101059_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0001-706X(01)00202-9","article-title":"Pathogenesis of Chagas heart disease: role of autoimmunity","volume":"81","author":"Engman","year":"2002","journal-title":"Acta Trop"},{"issue":"11","key":"10.1016\/j.lana.2025.101059_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-3024.2009.01108.x","article-title":"The role of parasite persistence in pathogenesis of Chagas heart disease","volume":"31","author":"Gutierrez","year":"2009","journal-title":"Parasite Immunol"},{"issue":"2","key":"10.1016\/j.lana.2025.101059_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0167-5273(96)02592-2","article-title":"Antiadrenergic and muscarinic receptor antibodies in Chagas' cardiomyopathy","volume":"54","author":"Borda","year":"1996","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.lana.2025.101059_bib8","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1017\/S1462399410001560","article-title":"The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease","volume":"12","author":"Junqueira","year":"2010","journal-title":"Expert Rev Mol Med"},{"issue":"9","key":"10.1016\/j.lana.2025.101059_bib9","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.4049\/jimmunol.173.9.5688","article-title":"Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi","volume":"173","author":"Oliveira","year":"2004","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.lana.2025.101059_bib10","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.4049\/jimmunol.1003911","article-title":"Requirement of UNC93B1 reveals a critical role for TLR7 in host resistance to primary infection with Trypanosoma cruzi","volume":"187","author":"Caetano","year":"2011","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.lana.2025.101059_bib11","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/eji.1830221006","article-title":"The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta","volume":"22","author":"Gazzinelli","year":"1992","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.lana.2025.101059_bib12","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1128\/iai.62.11.5177-5182.1994","article-title":"Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro","volume":"62","author":"Vespa","year":"1994","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.lana.2025.101059_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nm.4023","article-title":"Killer lymphocytes use granulysin, perforin and granzymes to kill intracellular parasites","volume":"22","author":"Dotiwala","year":"2016","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.lana.2025.101059_bib14","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1128\/IAI.01459-08","article-title":"Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination","volume":"77","author":"de Alencar","year":"2009","journal-title":"Infect Immun"},{"issue":"Pt 3","key":"10.1016\/j.lana.2025.101059_bib15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1042\/bj3040793","article-title":"Lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas\u2019 disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi","volume":"304","author":"Almeida","year":"1994","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.lana.2025.101059_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2613.2009.00670.x","article-title":"Perforin-expressing cytotoxic cells contribute to chronic cardiomyopathy in Trypanosoma cruzi infection","volume":"91","author":"Silverio","year":"2010","journal-title":"Int J Exp Pathol"},{"issue":"3","key":"10.1016\/j.lana.2025.101059_bib17","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1128\/IAI.71.3.1185-1193.2003","article-title":"Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response","volume":"71","author":"Gomes","year":"2003","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.lana.2025.101059_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1084\/jem.174.3.539","article-title":"Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta)","volume":"174","author":"Silva","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.lana.2025.101059_bib19","first-page":"172","article-title":"Immunit\u00e9 partielle dans les infections \u00e0 Trypanosoma cruzi, transmission de ce trypanosome par Cimex rotundus. Role regulateur d\u00eas hotes intermediaires. Passage \u00e0 traversla peau","volume":"6","author":"Brumpt","year":"1913","journal-title":"Bull Soc Path Exotique"},{"issue":"1","key":"10.1016\/j.lana.2025.101059_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4269\/ajtmh.1993.49.143","article-title":"Field trial of vaccination against American trypanosomiasis (Chagas' disease) in dogs","volume":"49","author":"Basombrio","year":"1993","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.lana.2025.101059_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF00932410","article-title":"Negative tissue parasitism in mice injected with a noninfective clone of Trypanosoma cruzi","volume":"81","author":"Lima","year":"1995","journal-title":"Parasitol Res"},{"issue":"49","key":"10.1016\/j.lana.2025.101059_bib22","doi-asserted-by":"crossref","first-page":"19695","DOI":"10.1073\/pnas.1110030108","article-title":"Trypanosoma cruzi as an effective cancer antigen delivery vector","volume":"108","author":"Junqueira","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.lana.2025.101059_bib23","doi-asserted-by":"crossref","first-page":"e0347821","DOI":"10.1128\/mbio.03478-21","article-title":"Disruption of active trans-sialidase genes impairs egress from mammalian host cells and generates highly attenuated Trypanosoma cruzi parasites","volume":"13","author":"Burle-Caldas","year":"2022","journal-title":"mBio"},{"issue":"10","key":"10.1016\/j.lana.2025.101059_bib24","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.4049\/jimmunol.179.10.6889","article-title":"Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming","volume":"179","author":"Hoft","year":"2007","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.lana.2025.101059_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41541-023-00676-0","article-title":"ASP-2\/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas' disease","volume":"8","author":"Castro","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.lana.2025.101059_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41541-017-0010-z","article-title":"Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection","volume":"2","author":"Sanchez Alberti","year":"2017","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.lana.2025.101059_bib27","article-title":"The case for the development of a Chagas disease vaccine: why? How? When?","volume":"6","author":"Dumonteil","year":"2021","journal-title":"Trop Med Infect Dis"},{"issue":"5","key":"10.1016\/j.lana.2025.101059_bib28","doi-asserted-by":"crossref","first-page":"e0007413","DOI":"10.1371\/journal.pntd.0007413","article-title":"A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection","volume":"13","author":"Barry","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"29","key":"10.1016\/j.lana.2025.101059_bib29","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1016\/j.vaccine.2020.05.010","article-title":"Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques","volume":"38","author":"Dumonteil","year":"2020","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.lana.2025.101059_bib30","doi-asserted-by":"crossref","first-page":"e0009613","DOI":"10.1371\/journal.pntd.0009613","article-title":"alpha-Gal immunization positively impacts Trypanosoma cruzi colonization of heart tissue in a mouse model","volume":"15","author":"Rodrigues da Cunha","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.lana.2025.101059_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41541-019-0107-7","article-title":"A prophylactic alpha-Gal-based glycovaccine effectively protects against murine acute Chagas disease","volume":"4","author":"Portillo","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"8","key":"10.1016\/j.lana.2025.101059_bib32","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0264-410X(97)00277-6","article-title":"Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice","volume":"16","author":"Costa","year":"1998","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.lana.2025.101059_bib33","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1089\/hum.2006.17.898","article-title":"Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase","volume":"17","author":"Machado","year":"2006","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/j.lana.2025.101059_bib34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1089\/hum.2004.15.878","article-title":"Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase","volume":"15","author":"Vasconcelos","year":"2004","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.lana.2025.101059_bib35","doi-asserted-by":"crossref","first-page":"e1004594","DOI":"10.1371\/journal.ppat.1004594","article-title":"A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy","volume":"11","author":"Pereira","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.lana.2025.101059_bib36","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3389\/fimmu.2019.01456","article-title":"TcG2\/TcG4 DNA vaccine induces Th1 immunity against acute Trypanosoma cruzi infection: adjuvant and antigenic effects of heterologous T. Rangeli booster immunization","volume":"10","author":"Gupta","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.lana.2025.101059_bib37","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/infdis\/jiu480","article-title":"Oral multicomponent DNA vaccine delivered by attenuated Salmonella elicited immunoprotection against American trypanosomiasis","volume":"211","author":"Cazorla","year":"2015","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.lana.2025.101059_bib38","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jmii.2022.09.003","article-title":"Safety and preservation of cardiac function following therapeutic vaccination against Trypanosoma cruzi in rhesus macaques","volume":"56","author":"Dumonteil","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.lana.2025.101059_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.crimmu.2023.100066","article-title":"Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8(+) T-cells","volume":"4","author":"Poveda","year":"2023","journal-title":"Curr Res Immunol"},{"issue":"13","key":"10.1016\/j.lana.2025.101059_bib40","doi-asserted-by":"crossref","first-page":"15832","DOI":"10.1021\/acsami.3c18830","article-title":"Harnessing RNA technology to advance therapeutic vaccine antigens against Chagas disease","volume":"16","author":"Mancino","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"issue":"7","key":"10.1016\/j.lana.2025.101059_bib41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0169-4758(86)90193-6","article-title":"Why vaccines do not work in Chagas disease","volume":"2","author":"Brener","year":"1986","journal-title":"Parasitol Today"},{"key":"10.1016\/j.lana.2025.101059_bib42","doi-asserted-by":"crossref","first-page":"e200314","DOI":"10.1590\/0074-02760200314","article-title":"Why do we still have not a vaccine against Chagas disease?","volume":"117","author":"Camargo","year":"2022","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"9","key":"10.1016\/j.lana.2025.101059_bib43","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1586\/erv.12.85","article-title":"Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects","volume":"11","author":"Dumonteil","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"10.1016\/j.lana.2025.101059_bib44","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/17460441.2020.1806233","article-title":"Animal models of Chagas disease and their translational value to drug development","volume":"15","author":"Chatelain","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.lana.2025.101059_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1106315","article-title":"Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease","volume":"13","author":"Jones","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"10.1016\/j.lana.2025.101059_bib46","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1128\/AAC.42.10.2549","article-title":"Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi","volume":"42","author":"Michailowsky","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.lana.2025.101059_bib47","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/AAC.00779-08","article-title":"Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection","volume":"53","author":"Ferraz","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.lana.2025.101059_bib48","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1086\/342415","article-title":"Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure","volume":"186","author":"Romanha","year":"2002","journal-title":"J Infect Dis"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X25000699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X25000699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T18:53:10Z","timestamp":1746903190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X25000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":48,"alternative-id":["S2667193X25000699"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2025.101059","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The time has come for a vaccine against Chagas disease","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2025.101059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101059"}}